Rendering factor Xa zymogen-like as a therapeutic strategy to treat bleeding

Area of Science:

• Biochemistry
• Hemostasis
• Pharmacology

Background:

• Effective therapies for bleeding disorders are crucial.
• Current procoagulant agents like factor VIIa offer hemostasis.
• Novel approaches are needed to rapidly enhance clot formation.

Purpose of the Study:

• To review the biochemical properties of zymogen-like factor Xa.
• To discuss its preclinical assessment in various model systems.
• To explore future development prospects for bleeding treatment.

Main Methods:

• Exploration of zymogen-like factor Xa variants over the past decade.
• Assessment of variant conformation, protease inhibitor resistance, and cofactor interaction.
• Preclinical testing in diverse model systems to evaluate hemostatic efficacy.

Main Results:

• Zymogen-like factor Xa variants exhibit altered conformations, resisting protease inhibitors.
• Factor Va binding stabilizes variants, rescuing procoagulant activity at injury sites.
• Preclinical data demonstrate efficacy in stopping bleeding across various settings.
• Phase 1 studies indicate safety and tolerability; Phase 1b is ongoing for intracerebral hemorrhage.

Conclusions:

• Zymogen-like factor Xa represents a unique prohemostatic agent.
• Its engineered properties offer a novel therapeutic strategy for bleeding conditions.